97712-Noom’s Breaking the GLP-1 Cost Cycle

Noom’s Breaking the GLP-1 Cost Cycle - Tailored solutions that can enhance outcomes and save costs.

Noom’s Breaking the GLP-1 Cost Cycle white paper dives into the scale of the obesity crisis and how Noom’s two tailored solutions can enhance health outcomes and cost savings, including for those on GLP-1s or other anti-obesity medications.

Obesity is a complex, multifactorial disease that requires comprehensive medical attention and innovative treatment strategies. Within the next five years, we anticipate a seismic shift in healthcare: most organizations will extend coverage for GLP-1 medications to treat obesity. This change is inevitable as non-branded alternatives emerge and costs decrease.

Work Email

First Name

Last Name

Address Line 1

Phone

City

State

Country

Company Name

Job Title

Company Size

Industry

Do you have oversight into your company's benefits program?

Yes No

By submitting this form, I understand that Noom will process my personal information in accordance with their Privacy Policy.

All information that you supply is protected by our Privacy Policy

In order to provide you with this free service, we may share your business information with companies whose content you choose to view on this website.

By submitting your information you agree to our Terms of Use.

Third party cookies may be placed, to serve more relevant ads when you browse the web. You can learn more about those ads here.

Download the guide

To meet diverse employer needs, Noom is unveiling two tailored solutions, which can be supported either through an organization’s current pharmacy benefit manager (PBM) or through a full carve-out for GLP-1 weight loss medications. Both enable affordable access to GLP-1 medications.

Solution 1, Noom Med with an optional SmartRx plan, is designed to drive ROI for employers who cover GLP-1s.
Solution 2, Noom Weight with discounted access to employee-pay meds, is designed as a workforce-friendly, budget-conscious solution for employers who do not cover GLP-1s.

In our latest white paper, you’ll learn more about Noom’s solutions, and how to significantly boost your ROI and broaden access to GLP-1s now, regardless of your organization’s current coverage policies for obesity medications.

At Noom, we do not wait for tomorrow—we act today. Download now and find out how Noom helps address diverse employer needs while positioning you ahead of the curve as treatment options evolve.